Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

NCT02482532 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
7
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Gary Doolittle